News

Home > News & Events > University College London Hospitals NHS Foundation Trust (UCLH) Trials Medial EarlySign Software Tool in Prestigious qFIT Pilot Study

University College London Hospitals NHS Foundation Trust (UCLH) Trials Medial EarlySign Software Tool in Prestigious qFIT Pilot Study

University College London Hospitals NHS Foundation Trust (UCLH) Trials Medial EarlySign Software Tool in Prestigious qFIT Pilot Study
Date

December 19, 2017

The qFIT pilot study, the largest of its kind in the UK, aims to see if a simple stool test (known as a qFIT or FIT test) could effectively ‘rule out’ colorectal cancer in patients with abdominal symptoms and reduce the burden on colonoscopy services.

 

The first phase was launched in April 2017 and over 300 patients have been recruited to date through 32 GP practices and 11 hospitals across six NHS trusts in north central and east London and west Essex. The second phase extends the study to a total of 64 organisations (50 GP practices, 14 hospitals) in London and East Lancashire over the next six months

 

The study is trialling a decision support software tool developed by Medial EarlySign that could identify patients who are at high risk of having colorectal cancer. The software analyses conventional blood test results, age and gender and will be tested alongside with qFIT to see whether it could further improve the efficacy of the qFIT test in ruling out colorectal cancer.

 

Mr. Michael Machesney, pilot lead, chair of the London Cancer Colorectal Pathway Board and consultant colorectal surgeon, said:  “If we can successfully prove that the qFIT test can accurately ‘rule-out’ colorectal cancer for patients with lower abdominal symptoms, we can potentially stem the increasing need for colonoscopy resources and transform the way that colorectal cancer is diagnosed. This is good news for hospitals and good news for patients.”

 

Mr. Ori Geva, co-founder and chief executive officer of Medial EarlySign, said: “We believe this research will show the benefits and efficacy of our machine learning solution in support of the qFIT test. We use routine health records and lab test results to flag the level of associated increased risk for colorectal cancer, helping healthcare organizations stratify their population and isolate sub-populations to prioritise their resources for patients who need care most urgently.”

 

Read the full announcement here.